Creo Medical Group (LON:CREO) Releases Earnings Results

Creo Medical Group (LON:CREO) announced its quarterly earnings data on Friday. The company reported GBX (0.04) earnings per share for the quarter, Digital Look Earnings reports. Creo Medical Group had a net margin of 768.18% and a return on equity of 32.72%. The business had revenue of GBX 600 million during the quarter.

Creo Medical Group Stock Up 28.4%

Shares of LON:CREO opened at GBX 14.60 on Friday. Creo Medical Group has a 52 week low of GBX 9.52 and a 52 week high of GBX 18.50. The company has a debt-to-equity ratio of 6.90, a quick ratio of 2.19 and a current ratio of 5.28. The company has a market capitalization of £60.22 million, a PE ratio of -14.60 and a beta of 1.62. The company has a 50 day moving average price of GBX 12.08 and a two-hundred day moving average price of GBX 12.16.

Wall Street Analyst Weigh In

Separately, Shore Capital Group reaffirmed a “house stock” rating on shares of Creo Medical Group in a report on Thursday, April 16th.

About Creo Medical Group

Creo Medical is a medical device company focused on the development and commercialisation of minimally invasive electrosurgical devices, bringing advanced energy to endoscopy.

The Company’s vision is to improve patient outcomes through the development and commercialisation of a suite of electrosurgical medical devices, each enabled by CROMA, powered by Kamaptive. The Group has developed the CROMA powered by Kamaptive full-spectrum adaptive technology to optimise surgical capability and patient outcomes.